April 20, 2021Open Access

Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results From a Phase 3 Trial

Key Points

Key points are not available for this paper at this time.

Abstract

In patients with EoE, BOS 2.0 mg twice daily was superior to placebo in improving histologic, symptomatic, and endoscopic outcomes over 12 weeks. BOS 2.0 mg twice daily was well tolerated. ClinicalTrials.gov number: NCT02605837.

Read Full Paperexternally

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Hirano et al. (Tue,) studied this question.

synapsesocial.com/papers/69dd4b1499c691022d99bcac https://doi.org/https://doi.org/10.1016/j.cgh.2021.04.022

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis2016 · 229 citations
2Oral Viscous Budesonide: A Potential New Therapy for Eosinophilic Esophagitis in Children2007 · 244 citations
3Budesonide Is Effective in Adolescent and Adult Patients With Active Eosinophilic Esophagitis2010 · 519 citations
4Psychometric validation of the Dysphagia Symptom questionnaire in Eosinophilic Esophagitis patients treated with Oral Budesonide Suspension2015 · 9 citations
5Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review2018 · 45 citations

Demander à l'IA

Bookmark

View Full Paper